×
About 22,753 results

ALLMedicine™ Bladder Cancer Center

Research & Reviews  7,815 results

Burden of Coronary Heart Disease and Cancer from Dietary Exposure to Inorganic Arsenic ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9053568
Annals of Global Health; Liu J, Song W et. al.

May 19th, 2022 - Inorganic arsenic (iAs) can cause a wide range of health problems, including coronary heart disease (CHD) and lung, bladder, and skin cancer. Although dietary iAs intake is the primary source of iAs, the burden of CHD and cancers from dietary iAs ...

Clinical features and predictive biomarkers for bladder cancer in patients with Type 2 ...
https://doi.org/10.1002/dmrr.3546
Diabetes/metabolism Research and Reviews; Tonry CL, Evans RM et. al.

May 18th, 2022 - To identify clinical features and protein biomarkers associated with bladder cancer (BC) in individuals with type 2 diabetes mellitus presenting with haematuria. Data collected from the Haematuria Biomarker (HaBio) study was used in this analysis....

Venous thromboembolism risk in patients receiving neoadjuvant chemotherapy for bladder ...
https://doi.org/10.1016/j.urolonc.2022.04.006
Urologic Oncology; Garas SN, McAlpine K et. al.

May 18th, 2022 - There is limited evidence to inform thromboprophylaxis use for patients receiving neoadjuvant chemotherapy prior to surgery in bladder cancer. We sought to determine the incidence of venous thromboembolism (VTE) in patients receiving neoadjuvant c...

see more →

Guidelines  29 results

Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
https://doi.org/10.1016/j.annonc.2021.11.012
Annals of Oncology : Official Journal of the European Soc... Powles T, Bellmunt J et. al.

Dec 4th, 2021 - Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.|2021|Powles T,Bellmunt J,Comperat E,De Santis M,Huddart R,|drug therapy,therapeutic use,drug therapy,therapy,

The Genitourinary Pathology Society Update on Classification and Grading of Flat and Pa...
https://doi.org/10.1097/PAP.0000000000000308
Advances in Anatomic Pathology; Amin MB, Comperat E et. al.

Jun 16th, 2021 - The Genitourinary Pathology Society (GUPS) undertook a critical review of the recent advances in bladder neoplasia with a focus on issues relevant to the practicing surgical pathologist for the understanding and effective reporting of bladder canc...

The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1...
https://doi.org/10.1097/PAP.0000000000000309
Advances in Anatomic Pathology; Compérat E, Amin MB et. al.

Jun 16th, 2021 - The Genitourinary Pathology Society (GUPS) undertook a critical review of the recent advances in bladder cancer focusing on important topics of high interest for the practicing surgical pathologist and urologist. This review represents the second ...

ACR Appropriateness Criteria® Post-Treatment Surveillance of Bladder Cancer: 2021 Update.
https://doi.org/10.1016/j.jacr.2021.02.011
Journal of the American College of Radiology : JACR; , Allen BC et. al.

May 8th, 2021 - Urothelial cancer is the second most common cancer, and cause of cancer death, related to the genitourinary tract. The goals of surveillance imaging after the treatment of urothelial cancer of the urinary bladder are to detect new or previously un...

European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Ca...
https://doi.org/10.1016/j.eururo.2020.03.055
European Urology; Witjes JA, Bruins HM et. al.

May 4th, 2020 - This overview presents the updated European Association of Urology (EAU) guidelines for muscle-invasive and metastatic bladder cancer (MMIBC). To provide practical evidence-based recommendations and consensus statements on the clinical management ...

see more →

Drugs  19 results see all →

Clinicaltrials.gov  344 results

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-...
https://clinicaltrials.gov/ct2/show/NCT03924856

May 13th, 2022 - A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eligible patients.

Study of CG0070 Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
https://clinicaltrials.gov/ct2/show/NCT04452591

May 13th, 2022 - An open-label trial designed to evaluate CG0070 + DDM in patients with NMIBC who have failed prior BCG therapy. Single treatment arm that will enroll up to 110 patients with carcinoma in situ with or without concomitant high-grade Ta or T1 papilla...

En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
https://clinicaltrials.gov/ct2/show/NCT04235764

May 13th, 2022 - Background: Bladder cancer is the sixth most common cancer in the United States, disproportionately affecting more men than women. The gold standard for the surgical treatment and diagnosis of non-muscle invasive bladder cancer is transurethral re...

Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT01352962

May 13th, 2022 - BACKGROUND: Gemcitabine plus carboplatin is an accepted first-line therapy in patients unfit for cisplatin chemotherapy with metastatic urothelial carcinoma or other solid tumor malignancies. Both non-clinical and clinical data support targeting a...

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy
https://clinicaltrials.gov/ct2/show/NCT04660344

May 12th, 2022 - This is a global Phase III, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with placebo in participants with MIBC who are ctDNA positive and are at h...

see more →

News  874 results

Stop Calling It Cancer; AI Gets a Win in Bladder Cancer; Lack of Price Transparency
https://www.medpagetoday.com/hematologyoncology/prostatecancer/98370

Apr 22nd, 2022 - A group of prostate cancer specialists, joined by MedPage Today contributor and prostate cancer patient Howard Wolinsky, made a case to stop referring to low-grade prostate cancer (Gleason ≤6) as cancer. (Journal of Clinical Oncology) The Internat...

Cancer Group Urges Oncologists to Fight Medical Misinformation
https://www.medpagetoday.com/hematologyoncology/othercancers/98033

Apr 4th, 2022 - Healthcare professionals need to be engaged in research to better understand cancer misinformation, how to combat it, and how to reach the population most affected by online health misinformation, according to a Collaboration for Outcomes Using So...

Neoadjuvant Atezolizumab/Chemo Shows Encouraging Efficacy in Muscle-Invasive Bladder Cancer
https://www.onclive.com/view/neoadjuvant-atezolizumab-chemo-shows-encouraging-efficacy-in-muscle-invasive-bladder-cancer

Mar 23rd, 2022 - The addition of atezolizumab (Tecentriq) to neoadjuvant gemcitabine and cisplatin (GC) generated a high rate of non–muscle-invasive downstaging following radical cystectomy, which correlated with improved relapse-free survival (RFS) and overall su...

Overuse of Surveillance in Bladder Cancer, Despite Guidelines
https://www.medscape.com/viewarticle/970698

Mar 22nd, 2022 - Clinicians are not following guidelines that recommend a de-escalation in surveillance for patients with low-risk non–muscle-invasive bladder cancer (NMIBC), a new study concludes.   These cancers are associated with low rates of recurrence, progr...

Neoadjuvant Enfortumab Vedotin Demonstrates Encouraging Activity in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
https://www.onclive.com/view/neoadjuvant-enfortumab-vedotin-demonstrates-encouraging-activity-in-cisplatin-ineligible-muscle-invasive-bladder-cancer

Mar 18th, 2022 - Enfortumab vedotin (Padcev) produced promising antitumor activity when used as neoadjuvant treatment in patients with muscle invasive bladder cancer (MIBC) who were not eligible for cisplatin, according to preliminary findings from cohort H of the...

see more →

Patient Education  20 results see all →